Fycompa

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

perampanel

Доступно од:

Eisai GmbH

АТЦ код:

N03AX22

INN (Међународно име):

perampanel

Терапеутска група:

Antiepileptics, , Other antiepileptics

Терапеутска област:

Epilepsies, Partial

Терапеутске индикације:

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Резиме производа:

Revision: 32

Статус ауторизације:

Authorised

Датум одобрења:

2012-07-23

Информативни летак

                                69
B. PACKAGE LEAFLET
70
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FYCOMPA 2 MG, 4 MG, 6 MG, 8 MG, 10 MG, AND 12 MG FILM-COATED TABLETS
Perampanel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Fycompa is and what it is used for
2.
What you need to know before you take Fycompa
3.
How to take Fycompa
4.
Possible side effects
5.
How to store Fycompa
6.
Contents of the pack and other information
1.
WHAT FYCOMPA IS AND WHAT IT IS USED FOR
Fycompa contains a medicine called perampanel. It belongs to a group
of medicines called
anti epileptics. These medicines are used to treat epilepsy - where
someone has repeated fits (seizures).
It has been given to you by your doctor to reduce the number of fits
that you have.
Fycompa is used in association with other antiepileptic drugs to treat
certain forms of epilepsy:
In adults, adolescents (aged 12 years and older), and children (from 4
to 11 years)
-
It is used to treat fits that affect one part of your brain (called a
“partial seizure”).
-
These partial seizures may or may not then be followed by a fit
affecting all of your brain
(called a “secondary generalisation”).
In adults and adolescents (aged 12 years and older), and children
(from 7 to 11 years)
-
It is also used to treat certain fits that affect all of your brain
from the start (called “generalised
seizures”) and cause convulsions or staring spells.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE FYCOMPA
DO NOT TAKE FYCOMPA:
-
If you have ever developed a severe skin rash or skin peeling
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Fycompa 2 mg film-coated tablets
Fycompa 4 mg film-coated tablets
Fycompa 6 mg film-coated tablets
Fycompa 8 mg film-coated tablets
Fycompa 10 mg film-coated tablets
Fycompa 12 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fycompa 2 mg film-coated tablets
Each film-coated tablet contains 2 mg perampanel.
Excipient with known effect: Each 2 mg tablet contains 78.5 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 4 mg film-coated tablets
Each film-coated tablet contains 4 mg perampanel.
Excipient with known effect: Each 4 mg tablet contains 157.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 6 mg film-coated tablets
Each film-coated tablet contains 6 mg perampanel.
Excipient with known effect: Each 6 mg tablet contains 151.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 8 mg film-coated tablets
Each film-coated tablet contains 8 mg perampanel.
Excipient with known effect: Each 8 mg tablet contains 149.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 10 mg film-coated tablets
Each film-coated tablet contains 10 mg perampanel.
Excipient with known effect: Each 10 mg tablet contains 147.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 12 mg film-coated tablets
Each film-coated tablet contains 12 mg perampanel.
Excipient with known effect: Each 12 mg tablet contains 145.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Fycompa 2 mg film-coated tablets
Orange, round, biconvex tablet, engraved with E275 on one side and
‘2’ on other side
Fycompa 4 mg film-coated tablets
Red, round, biconvex tablet, engraved with E277 on one side and
‘4’ on other side
Fycompa 6 mg film-coated tablets
Pink, round, biconvex tablet, engrav
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 10-05-2023
Информативни летак Информативни летак Шпански 10-05-2023
Информативни летак Информативни летак Чешки 10-05-2023
Информативни летак Информативни летак Дански 10-05-2023
Информативни летак Информативни летак Немачки 10-05-2023
Информативни летак Информативни летак Естонски 10-05-2023
Информативни летак Информативни летак Грчки 10-05-2023
Информативни летак Информативни летак Француски 10-05-2023
Карактеристике производа Карактеристике производа Француски 10-05-2023
Информативни летак Информативни летак Италијански 10-05-2023
Карактеристике производа Карактеристике производа Италијански 10-05-2023
Извештај о процени јавности Извештај о процени јавности Италијански 13-01-2021
Информативни летак Информативни летак Летонски 10-05-2023
Информативни летак Информативни летак Литвански 10-05-2023
Карактеристике производа Карактеристике производа Литвански 10-05-2023
Информативни летак Информативни летак Мађарски 10-05-2023
Информативни летак Информативни летак Мелтешки 10-05-2023
Информативни летак Информативни летак Холандски 10-05-2023
Карактеристике производа Карактеристике производа Холандски 10-05-2023
Информативни летак Информативни летак Пољски 10-05-2023
Информативни летак Информативни летак Португалски 10-05-2023
Карактеристике производа Карактеристике производа Португалски 10-05-2023
Извештај о процени јавности Извештај о процени јавности Португалски 13-01-2021
Информативни летак Информативни летак Румунски 10-05-2023
Информативни летак Информативни летак Словачки 10-05-2023
Информативни летак Информативни летак Словеначки 10-05-2023
Карактеристике производа Карактеристике производа Словеначки 10-05-2023
Извештај о процени јавности Извештај о процени јавности Словеначки 13-01-2021
Информативни летак Информативни летак Фински 10-05-2023
Информативни летак Информативни летак Шведски 10-05-2023
Информативни летак Информативни летак Норвешки 10-05-2023
Информативни летак Информативни летак Исландски 10-05-2023
Карактеристике производа Карактеристике производа Исландски 10-05-2023
Информативни летак Информативни летак Хрватски 10-05-2023

Обавештења о претрази у вези са овим производом

Погледајте историју докумената